Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Further Reading from MarketBeat.com A Fresh IPO That Long-Term Investors Shouldn't IgnoreBy Jordan Chussler. Published: 1/14/2026. 
Key Points - While IPOs are often labeled as high-risk startups, some are worthy of more conservative investors’ attention.
- Aktis Oncology’s IPO—the first biotech IPO of 2026—resulted in a $318 million raise, with the biotech firm receiving $100 million in backing from Big Pharma giant Eli Lilly.
- The company, which now has a market cap of $3.34 billion, develops radiopharmaceuticals and is positioned for long-term success after being listed on the Nasdaq.
For speculative investors, the start of each year is a good time to revisit an initial public offering (IPO) calendar. Almost every week, companies go public, and a handful often offer considerable short-term upside potential. They also carry substantial downside risk. Still, even conservative investors who favor caution should not automatically dismiss every recent IPO; some newly public stocks may deserve a place in buy-and-hold portfolios. While President Trump's official salary is $400,000 per year... his tax returns reveal he's been collecting up to $250,000 PER MONTH from one hidden source. Until recently, most Americans couldn't touch the type of investment that makes up this investment. But thanks to Executive Order 14330, that just changed. If you love investing in disruptive new companies... Discover how to invest in the fund Trump uses to collect this income >> One biotechnology company in the healthcare sector that recently went public could be one such case. Last Year's IPO Success Stories Last year provides a strong example of why these companies shouldn't be written off by investors with lower risk tolerances. AI cloud computing provider CoreWeave (NASDAQ: CRWV), which went public in March 2025, is up nearly 123% since then. Short-term speculators may have profited from its nearly 359% surge before 30 days on the Nasdaq, but long-term holders have also seen strong returns. Others, such as Medline (NASDAQ: MDLN), refute the idea that IPOs are only risky startups. The medical products and services provider, which debuted publicly in December 2025, was founded in 1966 and already boasts a market cap in excess of $55 billion. Similarly, Smithfield Foods (NASDAQ: SFD)—famous for its ubiquitous packages of bacon—waited 89 years before its IPO. Since going public in January 2025, the stock is up nearly 5% and has rewarded shareholders with a dividend that currently yields 4.44%, or $1 per share annually, making it an immediate consideration for income investors. After its IPO and with shares hitting the market on Jan. 9, Aktis Oncology (NASDAQ: AKTS), a maker of radiopharmaceuticals, is hoping for a similar outcome in 2026 and beyond. Why Are Radiopharmaceuticals Important? Aktis Oncology specializes in radiopharmaceuticals—a subset of nuclear medicine that uses radioactive drugs for both diagnostics and treatment of conditions including cancer, heart disease and neurological disorders. Radiopharmaceuticals combine radioactive isotopes with a targeting module that seeks out particular cells (for example, cancer cells) to deliver localized doses of radiation, minimizing harm to healthy tissue compared with conventional treatments. According to industry consultancy Grand View Research, the global nuclear medicine market was estimated at nearly $18 billion in 2024 and is forecast to reach nearly $35 billion by 2030, a compound annual growth rate of 10.16%. Importantly for Boston-based Aktis Oncology, Grand View Research notes that North America accounts for nearly 43% of the global nuclear medicine market, with the United States as the dominant player. Aktis Oncology's Clinical-Stage Biotechnology Wall Street expects biotech IPOs to rebound in 2026 after funding shifts in 2025 notably slowed listings from the healthcare sector. Aktis Oncology, which debuted on the Nasdaq on Jan. 9, was the first biotech IPO of 2026 and raised one of the largest amounts for a biotech listing in recent memory. With $318 million in IPO proceeds, the firm now has a market cap of about $3.34 billion. According to the company's prospectus, the executive team includes experts in drug development, approval and commercialization, with management having participated in bringing 14 currently FDA-approved products to market. At a technical level, Aktis develops targeted alpha radiopharmaceuticals, a class of precision cancer drugs that use proprietary technology to target solid tumors while sparing healthy tissue. Aktis Oncology's Eli Lilly Connection Aktis is a clinical-stage, pre-revenue company, but that did not prevent it from attracting attention from Eli Lilly (NYSE: LLY), which anchored its IPO. According to Reuters, Eli Lilly purchased $100 million worth of AKTS shares in the IPO. That purchase builds on a 2024 collaboration in which Eli Lilly committed $60 million in cash and made an equity investment in Aktis to develop tumor-targeting radiopharmaceuticals, with potential milestone payments exceeding $1 billion. The significance of Eli Lilly's backing cannot be overstated. With a market cap around $1.01 trillion, Eli Lilly is the largest Big Pharma company and saw net income jump nearly 109% year-over-year from 2023 to 2024. That momentum is likely to be a focal point when Lilly reports Q4 and full-year 2025 financials on Feb. 5. Between its equity stake and the $100 million AKTS share purchase, the maker of Zepbound now has a sizable financial interest in the biotech startup's success.
| 
